Targeting Adaptive Stress and Innate Immunity
We have developed a deep and differentiated pipeline of therapy candidates that address dynamic drivers of treatment resistance, cancer relapse and metastasis.
By combining our translational expertise with our proprietary QuAD3 platform, we believe we can enhance our clinical development efforts by identifying patients most likely to respond to our therapeutic candidates, while simultaneously enhancing our discovery efforts to expand our pipeline of innovative therapeutic candidates in cancer and other indications.